Markham’s new gig
Executive Summary
Former Aventis Vice Chairman and Chief Operating Officer Richard Markham joins Care Capital, a Princeton, N.J.-based venture capital firm focusing on later stage investments. Markham was one of several Aventis senior executives to depart after the company was acquired by Sanofi (1"The Pink Sheet" Sept. 6, 2004, p. 3). He joins former SmithKline Beecham CEO Jan Leschly and Novartis CEO-Pharmaceuticals Jerry Karabelas, PhD, who both serve as partners of the venture capital firm. Prior to Markham's tenure at Aventis (and predecessor companies), he spent 20 years at Merck and was the company's first choice to replace CEO Roy Vagelos, MD, when he retired in 1993; he could be an intriguing choice to replace CEO Ray Gilmartin when he retires in 2006 (2"The Pink Sheet" Oct. 18, 2004, p. 4). However, Markham said he intends to remain in the venture capital industry on a permanent basis...
You may also be interested in...
Merck CEO Search Expands: Is Company Now A Turnaround Story?
Merck is expanding its CEO succession search while revising the job description to take into account the challenges posed by the Vioxx withdrawal
Sanofi-Aventis Begins Operations; Markham, Senior Aventis Execs Depart
Sanofi-Aventis is beginning operations as a top 10 pharmaceutical company in the U.S
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”